4DMedical has received approval from Australia's Therapeutic Goods Administration (TGA) for its CT:VQ ventilation-perfusion imaging software, enabling commercial deployment across Australia.
CT:VQ derives regional ventilation and perfusion data from routine, non-contrast chest CT scans without the need for radiotracers, injected contrast agents, or dedicated nuclear medicine infrastructure, the company said. The software integrates with existing CT imaging equipment.
CT:VQ previously received U.S. Food and Drug Administration (FDA) clearance in 2025 and holds regulatory clearance in the European Union, U.K., Canada, and New Zealand, according to 4DMedical. U.S. sites using the software include Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, University of Miami, and SimonMed.
